3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
1
Conditions
Keratosis, Actinic
6
Neoplasms
5
Melanoma
3
Warts
2
Prostatic Neoplasms
2
Neoplasm Metastasis
2
Hyperthermia
2
Hematologic Neoplasms
2
Hemangioma
2
Uveal Melanoma
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Squamous Intraepithelial Lesions
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumors Harboring NTRK Fusion
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Sarcoma
1
Recurrence
1
Polycystic Ovary Syndrome
1
Pituitary Neoplasms
1
Pelvic Neoplasms
1
Pain
1
Ovarian Neoplasms
1
Obesity
1
Nonmelanoma Skin Cancers
1
Mucositis
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Lymphoma, T-Cell
1
Lung Neoplasms
1
Interventions
pasireotide
7
Cabergoline
7
Temozolomide
3
Propofol
3
Hydrocortisone
3
Dexmedetomidine
3
lanreotide
2
Sevoflurane
2
Saline Solution
2
Rosiglitazone
2
Proton Therapy
2
Octreotide
2
Dexamethasone
2
Desflurane
2
pegvisomant
1
parecoxib
1
lutetium Lu 177 dotatate
1
loxoprofen
1
farletuzumab
1
entinostat
1
corticorelin ovine
1
antineoplaston AS 2-1
1
antineoplaston A10
1
Yoga
1
Trimethoprim
1
Transcranial Magnetic Stimulation
1
Tranexamic Acid
1
Tramadol
1
Thyrotropin-Releasing Hormone
1
TBR-760
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Pituitary Neoplasms
×
Solutions
×
Clear all
NCT03439709
2018-03-01
MERGE
Samsung Medical Center
Phase 3
Unknown
90 enrolled